Canada markets open in 8 hours 17 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
20.83+0.29 (+1.41%)
At close: 04:00PM EST
20.75 -0.08 (-0.38%)
After hours: 07:49PM EST
Full screen
Loading interactive chart...
  • Simply Wall St.

    Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?

    With the business potentially at an important milestone, we thought we'd take a closer look at Cassava Sciences, Inc.'s...

  • GlobeNewswire

    Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results

    Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's.Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results for 76-week Phase 3 trial expected approximately mid-year 2025.MRI safety data suggests simufilam is not associated with ARIA.$142.4 Million in cash and cash equivalents at September 30, 2023. AUSTIN, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc

  • GlobeNewswire

    Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

    1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025. AUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate